Robert F. Green
Robert F. Green is a founding partner of Green, Griffith & Borg-Breen LLP. He practices IP law exclusively, with a concentration in pharmaceutical, biochemical and chemical litigation and opinions.
Mr. Green has represented clients under the Hatch- Waxman Act since it was passed in 1984. As lead counsel in Hatch-Waxman litigation, he has litigated patents covering over 40 drug products, serving both plaintiffs and defendants. Mr. Green has argued numerous pharmaceutical patent appeals before the U.S. Court of Appeals for the Federal Circuit. He has broad experience managing patent portfolios, counselling and rendering opinions on patent validity and infringement. He also specializes in formulating patent strategies in the pharmaceutical field for both brand and generic pharmaceutical companies.
Recently, Mr. Green successfully defended Dexcel against alleged infringement of Takeda's Orange Book-listed patents for lansoprazole delayed-released orally disintegrating tablets ("ODT"). As a result of this ruling, Dexcel launched the first lansoprazole ODT product sold Over-The-Counter ("OTC") in the US market.
In addition, Mr. Green has been instrumental in obtaining favorable settlements for Horizon Pharma in litigations related to Abbreviated New Drug Applications filed by various generic drug companies. Mr. Green also was counsel for Cipla in litigation relating to Cipla's ANDA that sought approval to market a generic equivalent to Helsinn's AloxiÂ® palonosetron product. That litigation settled with a favorable generic product entry date.
Bob has been named a 2018 "Global IP Star" by Managing IP and has been listed in Intellectual Asset Management's (IAM) Patent 1000 in Litigation (2015-2018). Bob has been selected as one of The Best Lawyers in AmericaÂ© (2016-2019) and has been listed as a "Life Sciences Star" by LMG Life Sciences (2012-2018). He has been selected by his peers as a Leading Lawyer in Intellectual Property Law, Leading Lawyers Network (2004-2018), and has also been featured in Leading Lawyers magazine. Bob has been recognized by Illinois Super Lawyers in Intellectual Property Litigation (2009-2018). In 2011, Bob was recognized as one of "The World's Leading Patent Litigators" in Intellectual Asset Management's IAM Patent Litigation 250. In 2010, Bob was named as one of "The World's Leading Life Sciences Patent Litigators" in Intellectual Asset Management's IAM Life Sciences 250.
Mr. Green previously was Vice President of Leydig, Voit & Mayer, the inside Patent Counsel for Celanese Chemical Company, and the inside IP counsel for the U.S. chemical division for Akzona (now AkzoNobel). Mr. Green's successes include many from which his clients were awarded market exclusivity, including the products ZantacÂ®, OTC omeprazole tablets, PlendilÂ®, and PlatinolÂ®.
Last updated September 2018